A Phase 2/3 interventional study of Placebo and AVP-786 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 72 sites in 4 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 55th largest by enrollment of the 111 interventional ones that give a count, is one of 13 that started in 2019, is one of 4 in phase 2/3, and was the 92nd registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–74
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–55 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 14 · Phase 3 54 · Phase 4 13
First in 1998; this study’s year is marked. 13 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 125 across the 111 interventional studies, 281 across the 8 observational. Of the 111 that completed or were terminated, 64 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
2 of the studies in Schizophrenia by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05325645Phase 3Otsuka Pharmaceutical Co., Ltd.Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | 2027-09 |
| NCT07455084Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults | 2026-12-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received AVP-786 matching placebo capsules, orally, twice a day (BID) over a 3-week run-in period.
Drug: Placebo
Participants received AVP-786-28/4.9 (deudextromethorphan hydrobromide (d6-DM) 28 milligrams (mg)/quinidine sulfate (Q) 4.9 mg) capsule, along with AVP-786 matching placebo capsule, orally, once daily (QD) for 3 days followed by AVP-786-28/4.9 capsule, orally, BID for the next 4 days of titration period. Following the 1-week titration period, participants received AVP-786-42.63/4.9 (d6-DM 42.63 mg/Q 4.9 mg), orally, BID for the remaining 11 weeks of the DBT period.
Drug: AVP-786
Participants received AVP-786 matching placebo capsules, orally, BID over a 12-week DBT period.
Drug: Placebo
oral capsules
Drug pages: Deudextromethorphan · Quinidine
oral capsules
Change From Baseline (Week 3) to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors Score
The PANSS is a validated clinical scale used as a reliable and valid measure of the negative and positive symptom of schizophrenia. PANSS consists of three subscales: a total of 30 disparate items. Each item's severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS marder negative factors score is comprised of the following 7 items of the 30-item PANSS: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation and active social avoidance. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). PANSS total score range is 30 to 210, with higher scores indicating more severe symptoms. Negative change from baseline indicates improvement. Baseline is defined as the end of the placebo run-in period (Week 3), and to be the last assessment prior to the first dose of study drug.
Time frame: Baseline (Week 3); Week 15
Change From Baseline (Week 3) to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom Score
NSA-16=clinician-rated scale assessing presence, severity, \& range of negative symptoms associated with schizophrenia. It consists of 16 items \& uses 5-factor model to describe negative symptoms: communication (1-4, range=4-24), emotional/affective (5-7, range=3-18), social involvement (8-10, range=3-18), motivational (11-14, range=4-24), \& retardation (15-16, range=3-18) \&Global Negative Symptom Rating. NSA-16 items are rated on 6-point scale, 1=behavior is normal to 6=behavior severely reduced. Each item admits score of 9 if item is not ratable. Global Negative Symptom Rating range is 1=no evidence of symptoms to 7=extremely severe symptoms. 16 items yield a total of 16-96, with higher score indicating greater clinical severity of symptoms. Global rating range is 1-7, with higher score indicating extremely severe symptom. If more than 3 items were not ratable, total score was not evaluable \& was regarded as missing. Negative change from baseline indicates improvement.
Time frame: Baseline (Week 3); Week 15
Change From Baseline (Week 3) to Week 15 in the Patient Global Impression of Severity (PGI-S) Score
The severity of participants illness with respect to their schizophrenia was rated using a 7-point PGI-S. PGI-S scores range from 1 to 7, where 1= normal, not at all ill, 2= borderline ill, 3=mildly ill, 4=moderately ill, 5= markedly ill, 6=severely ill, 7=extremely ill. Missing PGI-S rating were not imputed. Negative change from baseline indicates improvement. Baseline is defined as the end of the placebo run-in period (Week 3), and to be the last assessment prior to the first dose of study drug.
Time frame: Baseline (Week 3); Week 15
Patient Global Impression of Change (PGI-C) Score
The PGI-C is a 7-point (1-7) participant-rated scale used to assess treatment response with respect to schizophrenia as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Missing PGI-C rating were not imputed. .
Time frame: At Weeks 6, 9, 12 and 15
Participants took part in this study at 65 investigative sites in Bulgaria, Poland, and the United States including Puerto Rico from 15 February 2019 to 23 May 2023.
| Milestone | Placebo (Run-in Period) | AVP-786 | Placebo |
|---|---|---|---|
| Started | 136 | 0 | 0 |
| Placebo responders | 10 | 0 | 0 |
| Placebo non-responders | 115 | 0 | 0 |
| Completed | 125 | 0 | 0 |
| Not completed | 11 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 |
| Withdrew: Reason not specified | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Non-compliance | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Milestone | Placebo (Run-in Period) | AVP-786 | Placebo |
|---|---|---|---|
| Started | 0 | 65 | 60 |
| Completed | 0 | 57 | 52 |
| Not completed | 0 | 8 | 8 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Noncompliance with study drug | 0 | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 2 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 4 |
The PANSS is a validated clinical scale used as a reliable and valid measure of the negative and positive symptom of schizophrenia. PANSS consists of three subscales: a total of 30 disparate items. Each item's severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS marder negative factors score is comprised of the following 7 items of the 30-item PANSS: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation, motor retardation and active social avoidance. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). PANSS total score range is 30 to 210, with higher scores indicating more severe symptoms. Negative change from baseline indicates improvement. Baseline is defined as the end of the placebo run-in period (Week 3), and to be the last assessment prior to the first dose of study drug.
| score on a scale | AVP-786 | Placebo |
|---|---|---|
| Change From Baseline (Week 3) to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors Score | -2.3 ± 0.47 | -2.5 ± 0.49 |
NSA-16=clinician-rated scale assessing presence, severity, \& range of negative symptoms associated with schizophrenia. It consists of 16 items \& uses 5-factor model to describe negative symptoms: communication (1-4, range=4-24), emotional/affective (5-7, range=3-18), social involvement (8-10, range=3-18), motivational (11-14, range=4-24), \& retardation (15-16, range=3-18) \&Global Negative Symptom Rating. NSA-16 items are rated on 6-point scale, 1=behavior is normal to 6=behavior severely reduced. Each item admits score of 9 if item is not ratable. Global Negative Symptom Rating range is 1=no evidence of symptoms to 7=extremely severe symptoms. 16 items yield a total of 16-96, with higher score indicating greater clinical severity of symptoms. Global rating range is 1-7, with higher score indicating extremely severe symptom. If more than 3 items were not ratable, total score was not evaluable \& was regarded as missing. Negative change from baseline indicates improvement.
| score on a scale | AVP-786 | Placebo |
|---|---|---|
| Change From Baseline (Week 3) to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom Score | -0.4 ± 0.10 | -0.5 ± 0.10 |
The severity of participants illness with respect to their schizophrenia was rated using a 7-point PGI-S. PGI-S scores range from 1 to 7, where 1= normal, not at all ill, 2= borderline ill, 3=mildly ill, 4=moderately ill, 5= markedly ill, 6=severely ill, 7=extremely ill. Missing PGI-S rating were not imputed. Negative change from baseline indicates improvement. Baseline is defined as the end of the placebo run-in period (Week 3), and to be the last assessment prior to the first dose of study drug.
| score on a scale | AVP-786 | Placebo |
|---|---|---|
| Change From Baseline (Week 3) to Week 15 in the Patient Global Impression of Severity (PGI-S) Score | -0.3 ± 0.16 | -0.4 ± 0.16 |
The PGI-C is a 7-point (1-7) participant-rated scale used to assess treatment response with respect to schizophrenia as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Missing PGI-C rating were not imputed. .
| score on a scale | AVP-786 | Placebo |
|---|---|---|
| Week 6 | 3.1 ± 1.07 | 3.0 ± 1.05 |
| Week 9 | 2.8 ± 1.10 | 2.9 ± 0.98 |
| Week 12 | 2.9 ± 1.15 | 2.9 ± 1.05 |
| Week 15 | 2.8 ± 1.20 | 2.9 ± 1.00 |
Collected over From the first dose of the study drug to end of follow up period (Up to Week 19). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Run-in Period) | 0/136 (0%) | 0/136 (0%) | 20/136 (14.7%) |
| AVP-786 | 0/65 (0%) | 2/65 (3.1%) | 25/65 (38.5%) |
| Placebo | 0/60 (0%) | 0/60 (0%) | 14/60 (23.3%) |
| Event | Placebo (Run-in Period) | AVP-786 | Placebo |
|---|---|---|---|
| CellulitisInfections and infestations | 0/136 | 1/65 | 0/60 |
| PneumoniaInfections and infestations | 0/136 | 1/65 | 0/60 |
| Event | Placebo (Run-in Period) | AVP-786 | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 3/136 | 2/65 | 2/60 |
| Back painMusculoskeletal and connective tissue disorders | 0/136 | 0/65 | 2/60 |
| DizzinessNervous system disorders | 2/136 | 2/65 | 1/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/136 | 2/65 | 1/60 |
| NasopharyngitisInfections and infestations | 1/136 | 2/65 | 0/60 |
| Gamma-glutamyltransferase increasedInvestigations | 0/136 | 2/65 | 0/60 |
| Weight increasedInvestigations | 0/136 | 2/65 | 0/60 |
| FallInjury, poisoning and procedural complications | 0/136 | 2/65 | 0/60 |
| HypertensionVascular disorders | 0/136 | 2/65 | 0/60 |
| SomnolenceNervous system disorders | 2/136 | 0/65 | 1/60 |
Randomized Sample included all participants randomized into the double-blind phase of this study.
| Age, Continuous(years) | AVP-786 | Placebo | Total |
|---|---|---|---|
| Mean | 44.8 ± 9.54 | 44.0 ± 10.25 | 44.4 ± 9.86 |
| Sex: Female, Male(Participants) | AVP-786 | Placebo | Total |
|---|---|---|---|
| Female | 20 | 24 | 44 |
| Male | 45 | 36 | 81 |
| Ethnicity (NIH/OMB)(Participants) | AVP-786 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 7 | 13 |
| Not Hispanic or Latino | 42 | 40 | 82 |
| Unknown or Not Reported | 17 | 13 | 30 |
| Race/Ethnicity, Customized(Participants) | AVP-786 | Placebo | Total |
|---|---|---|---|
| White | 14 | 12 | 26 |
| Black or African American | 33 | 34 | 67 |
| Asian | 1 | 0 | 1 |
| Other | 0 | 1 | 1 |
| Missing | 17 | 13 | 30 |
| Patient Global Impression of Change (PGI-C) Score(score on a scale) | AVP-786 | Placebo | Total |
|---|---|---|---|
| Mean | 3.3 ± 0.91 | 3.5 ± 0.86 | 3.4 ± 0.89 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Feb 2019 to primary completion in May 2023, 51 months.
Results were first posted in Sep 2026, 3 years 4 months after primary completion. A results delay was requested in May 2024.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deudextromethorphan · Quinidine
Otsuka Pharmaceutical Development & Commercialization, Inc. →